Amiloidózis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TTR 56
• BCMA 11
• APOE 0
• SGLT2 0
• CD19 4
• MAPT 0
• CD38 0
• TNF 0
• APP 0
• BCL-2 0
• RET 0
• SNCA 0
• TREM2 0
• GPRC5D 2
• IL-1 0
• IL-6 0
• JAK 0
• LAG-3 0
• PPAR 0
• BACE1 0
• CFTR 0
• CXCR4 0
• EGFR 0
• HIF-1 0
• NRF2 0
• PARP 0
• PI3K 0
• TLR4 0
• TP53 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · K23

  TARGET-TTR: Targeted Artificial Intelligence-Driven Screening of Transthyretin Amyloid Cardiomyopathy in the Electronic Health Record

  Yale University· New Haven, Egyesült Államok· 170 964 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling the Role of Cerebral Amyloid-beta Angiopathy in Epilepsy: Inflammatory Pathways and Interneuron Dysfunction (EPICAA)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Németország· EU contribution 217 965 EUR· until 2029. febr.

• European Commission (Horizon Europe) · HORIZON-ERC

  The Mechanisms of neuronal silencing in Alzheimer’s Disease – investigation of cellular and network mechanisms in mouse models of β-amyloidosis (MONSil-AD)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 1 482 666 EUR· until 2030. dec.

• European Commission (Horizon 2020) · ERC-COG

  A unified drug discovery platform for protein misfolding diseases (ProMiDis)

  Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk· Vari-Athens, Görögország· EU contribution 1 972 000 EUR· until 2027. febr.

5 of 5 running projects, newest first. Listed amounts together: 171,0 E USD + 3,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

  NCT06983951· Beijing Boren Hospital· Frissítve: 2026. okt. 13.

  “Due to the promulgation of State Council Order No. 818, clinical trials of this category are prohibited.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

  NCT07626476· Beijing Boren Hospital· Frissítve: 2026. okt. 13.

  “Due to the promulgation of State Council Order No. 818, clinical trials of this category are prohibited.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

  NCT06769555· Institute of Hematology & Blood Diseases Hospital, China· Frissítve: 2026. ápr. 29.

  “The study protocol was withdrawn because, after modifications, the study transitioned from an Investigator-Initiated Trial (IIT) to an Investigational New Drug (IND) clinical trial. This change necessitated a multi-center approach.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

  NCT07250269· Gracell Biotechnologies (Shanghai) Co., Ltd.· Forrás

• Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

  NCT07524634· Case Comprehensive Cancer Center· Forrás

• A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

  NCT07081646· Alexion Pharmaceuticals, Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 3
• Gene Expression Profiling 3
• Sequence Analysis, RNA 3
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 2
• Mass Spectrometry 14
• Flow Cytometry 1
• Immunohistochemistry 14
• Positron-Emission Tomography 33
• Magnetic Resonance Imaging 95
• Machine Learning 13
• Deep Learning 4
• Cohort Studies 42
• Genome-Wide Association Study 2

• Cerebral Amyloid Angiopathy in Alzheimer Disease Continuum: Prevalence and Clinical Relevance in a Biomarker-Defined Memory Clinic Cohort.

  Neurology, 2026. nov.

• Circulating microRNAs reflect hemorrhagic MRI markers in cerebral amyloid angiopathy.

  Exp Neurol, 2026. okt.

• Clinical manifestations and cardiac abnormalities in systemic Amyloid A Amyloidosis.

  Int J Cardiol, 2026. okt.

• Comparison of scoring systems in the identification of transthyretin cardiac amyloidosis in a HFpEF cohort.

  Int J Cardiol, 2026. okt.

• Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy.

  JAMA Cardiol, 2026. okt.

• Prevalence and determinants of asymmetric septal hypertrophy (ASH) in diseases of left ventricular hypertrophy (LVH).

  Eur Heart J Cardiovasc Imaging, 2026. szept.

• Neuropathology of centenarians and supercentenarians: An autopsy study.

  Neurobiol Aging, 2026. szept.

• Early vs Delayed Steroid Treatment in Cerebral Amyloid Angiopathy-Related Inflammation: A Retrospective Cohort Study.

  Neurol Neuroimmunol Neuroinflamm, 2026. szept.

• LVH-Voltage Discordance and Myocardial Dysfunction in Wild-Type Transthyretin Cardiomyopathy: A Prospective Cohort Study.

  Echocardiography, 2026. szept.

• Neuropathological and vascular determinants of cerebral amyloid angiopathy risk: evidence from the NACC cohort.

  Alzheimers Res Ther, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.